Ask Warren

Naturecell

007390 · KOSDAQ · ₩007390 · 네이처셀

₩22,200▲ ₩50 (0.23%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −13.28%
Market cap
₩1.4T
Enterprise value
₩1.4T
P/E
—
P/B
22.7×
Dividend yield
0.0%
ROE
−4.3%
Net margin
−13.2%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−39.9% from the high

₩16,550Today: ₩21,750 – ₩22,400₩36,950

Returns

  • 1W−5.9%
  • 1M−8.8%
  • 3M−2.6%
  • 6M+15.9%
  • YTD+1.8%
  • 1Y−13.3%
Volume today
168,167
0.8× the 20-day average
Traded today
₩3.7B
Listed shares
64,435,056
EPS (12 months)
−₩42
Earnings yield −0.2%
SellBuy
AI research · InitiationNaturecell: Loss-Making Biotech Trades at High Sales and Book Multiples as Funding Activity ContinuesThe filed numbers show a company with modest revenue, recurring losses and negative cash flow, valued at a high multiple of sales and book value.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

40Quiet
  • BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
  • MomentumWeak-12.6% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩419M at the close (8.4% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 18 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 24.6% of trading value and pointed the same way 12 of 18 times.

  • 2× KODEX KOSDAQ150 Leverage −₩292M
  • -1× KODEX KOSDAQ150 Futures Inverse −₩72M
  • 2× TIGER KOSDAQ150 Leverage −₩36M
  • 2× RISE KOSDAQ150 Futures Leverage −₩14M
  • -1× TIGER KOSDAQ150 Futures Inverse −₩2.4M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 21,800

Basis −1.80% · implied rate −47.4%

Open interest 3,881 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Naturecell stock overview

Naturecell (네이처셀, KRX: 007390) is listed on KOSDAQ, in the Biotech & Pharma sector. Nature Cell is a South Korean company developing stem cell therapies from a patient's own fat-derived adult stem cells, with its lead candidate JointStem for knee osteoarthritis in clinical trials in the United States. Its shares closed at ₩22,200 on Oct 29, 2026, up 0.23% on the day, giving it a market value of ₩1.4T.

Key facts

Market cap
₩1.4T
Sector
Biotech & Pharma
Latest price change
+0.23%
As of
Oct 29, 2026
Main business
Nature Cell is a South Korean company developing stem cell therapies from a patient's own fat-derived adult stem cells, with its lead candidate JointStem for knee osteoarthritis in clinical trials in the United States.

Quick answers about Naturecell

What does Naturecell do?
Nature Cell is a South Korean company developing stem cell therapies from a patient's own fat-derived adult stem cells, with its lead candidate JointStem for knee osteoarthritis in clinical trials in the United States. Jucre brand sold through its own mall, home shopping and duty-free stores, and vegan health drinks sold through convenience stores, online malls and home shopping in Korea. S.
What is the market cap of Naturecell?
The market capitalisation of Naturecell was ₩1.4T at the close on Oct 29, 2026.
Who are the largest shareholders of Naturecell?
According to the latest official filings, the largest reported holders are RNL Regenerative Medicine Research Institute (17.87%, as of May 20, 2025); Ra Jeong-chan (1.61%, as of Mar 27, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.21%, as of Jul 31, 2026).
When is the next earnings report from Naturecell?
Korean companies rarely announce results dates in advance. Based on when Naturecell filed the same report in past years, its next 3q results is expected between Nov 11, 2026 and Nov 14, 2026.
Does the National Pension Service own Naturecell?
Yes. The National Pension Service held 0.44% of Naturecell shares as of Dec 31, 2025.

Company profile

Nature Cell is a South Korean company developing stem cell therapies from a patient's own fat-derived adult stem cells, with its lead candidate JointStem for knee osteoarthritis in clinical trials in the United States. It also makes stem cell culture media sold to researchers and manufacturers, cosmetics made from stem cell culture fluid under the Dr.Jucre brand sold through its own mall, home shopping and duty-free stores, and vegan health drinks sold through convenience stores, online malls and home shopping in Korea. Its U.S. subsidiary, Nature Cell America Inc., supports overseas development and promotion.

Written by AI from the company's latest annual report.

Korean name
네이처셀
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
라정찬
Founded
Aug 1971
Listed
Nov 1992
Listed shares
64,435,056
Fiscal year ends
Month 12
Website
www.naturecell.co.kr

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Naturecell / 네이처셀 / 007390 / KRX:007390

Source: KRX statistical information